Management reiterated guidance for 2026 revenues of $20 million to $30 million and 2027 revenues of $100 million to $200 million, aiming for EBITDA adjusted run rate breakeven in 2027. The PET cap ...
The company revised its 2026 revenue guidance to $20 million to $30 million and its 2027 revenue guidance to $100 million to $200 million, citing delays in CapFormer production and tariff impacts.